指南与共识泌尿男性生殖肿瘤支持与姑息治疗

缺乏共识提示未来临床研究的重要领域:晚期前列腺癌共识会议(APCCC)2019 结果

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
指南 / 共识 · Eur J Cancer · 2021-11-26

APCCC 2019 邀请 57 位专家对 123 个临床管理多选题投票,88 个(71.5%)未达共识(定义为 <75% 专家选择同一选项)。作者检索 clinicaltrials.gov 发现部分未共识问题有正在进行的 III 期试验,但许多问题无相应试验,激素治疗副作用及其管理仅见 II 期试验。缺乏共识几乎总提示现有证据缺口。

要点

  • 57 位专家对 123 个问题投票,88 个(71.5%)未达共识(<75% 选同一选项)。
  • 许多未共识问题无正在进行的 III 期试验;激素治疗副作用及管理仅见 II 期试验。
  • 缺乏共识几乎总提示证据缺口,需稳健且临床相关的试验填补。

核心结论

  • 缺乏共识几乎总提示现有证据存在缺口。
  • APCCC 2019 高比例未共识问题凸显晚期前列腺癌诊疗的复杂性及开展稳健、临床相关试验以高级别证据填补当前缺口的必要性。
  • 对未共识领域及正在进行的试验的综述提供了有用总结,提示未来可能很快达成共识的领域。
  • 该综述可帮助学术研究者识别并优先安排未来研究课题。

研究设计与样本

  • APCCC 2019 邀请 57 位专家组成的小组对 123 个临床管理多选题进行投票。
  • 未共识定义为 <75% 专家对同一答案选项投票;88 个(71.5%)问题未达共识。
  • 作者检索 clinicaltrials.gov 以识别这些未共识领域中正在进行的相关 III 期试验。

主要发现

  • 识别出若干与未共识问题相关的正在进行的 III 期试验。
  • 许多未共识问题似乎未被当前临床试验覆盖。
  • 值得注意的是,仅识别出 II 期试验(无 III 期试验)研究激素治疗的副作用及其管理。

关键数值与推荐

  • 未共识定义为 <75% 专家投票选择同一答案选项。
  • 123 个问题中 88 个(71.5%)未达共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 缺乏共识几乎总提示现有证据存在缺口。
  • 许多未共识问题似乎未被当前临床试验覆盖。
  • 激素治疗副作用及其管理仅见 II 期试验,无 III 期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Innovations in treatments, imaging and molecular characterisation have improved outcomes for people with advanced prostate cancer; however, many aspects of clinical management are devoid of high-level evidence. At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, many of these topics were addressed, and consensus was not always reached. The results from clinical trials will most reliably plus the gaps. METHODS: An invited panel of 57 experts voted on 123 multiple-choice questions on clinical management at APCCC 2019. No consensus was reached on 88 (71.5%) questions defined as <75% of panellists voting for the same answer option. We reviewed clinicaltrials.gov to identify relevant ongoing phase III trials in these areas of non-consensus. RESULTS: A number of ongoing phase III trials were identified that are relevant to these non-consensus issues. However, many non-consensus issues appear not to be addressed by current clinical trials. Of note, no phase III but only phase II trials were identified, investigating side effects of hormonal treatments and their management. CONCLUSIONS: Lack of consensus almost invariably indicates gaps in existing evidence. The high percentage of questions lacking consensus at APCCC 2019 highlights the complexity of advanced prostate cancer care and the need for robust, clinically relevant trials that can fill current gaps with high-level evidence. Our review of these areas of non-consensus and ongoing trials provides a useful summary, indicating areas in which future consensus may soon be reached. This review may facilitate academic investigators to identify and prioritise topics for future research.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vogl UM, Beer TM, Davis ID, et al. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2021. PMID: 34844839. doi:10.1016/j.ejca.2021.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。